Watch CBS News

Food and Drug Administration

aduhelm-product-biogen-843842-640x360.jpg

A new Alzheimer's drug brings hope, controversy

The FDA's recent approval of a new drug, Aduhelm, to clear the formation of amyloid plaques in the brain is potentially good news for the six million Americans who suffer from Alzheimer's disease. But the approval process for Aduhelm has stirred controversy. Correspondent Susan Spencer talks with experts about the clinical benefits of this new class of drugs; and with early-onset Alzheimer's patients, including a former neurologist who enrolled in an early trial of Aduhelm.

Show More
View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.